Iambic Therapeutics develops AI-driven platforms for drug discovery, focusing on optimizing medicines for specific disease profiles and addressing unmet patient needs. The company self-describes its approach as innovative and efficient.

Iambic Therapeutics

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

Join Sayan Mondal, Iambic Therapeutics Executive Director of Computational Chemistry and Co-Chair of the PDDP Summit, in a panel discussion on pioneering the biopharma landscape with Al-driven drug discovery and development. Precision Evolution Global

Date/time: October 13th, 12:10pm - 1:15pm PT

#drugdiscovery #artificialintelligence #machinelearning

Tune into Iambic co-founder and CEO Thomas Miller discussing the genesis and future of Iambic on BIOS!

Iambic Therapeutics (formerly known as Entos) announced the closing of its oversubscribed $100 million Series B financing round to advance AI-discovered therapeutics into clinical development. Concurrently, Iambic has entered a collaboration with NVIDIA to leverage NVIDIA technology to accelerate drug discovery. 

Said CEO Thomas Miller, “At Iambic, our world-class team has combined physics and AI to create a differentiated drug discovery platform that achieves a step-change in the speed and success rate for delivering best-in-class and first-in-class development candidates to clinic.” 

The funding will be used to advance multiple candidates into clinical development (including a selective brain-penetrant HER2 inhibitor and a selective dual CDK2/4 inhibitor), expand its pipeline with additional candidates, and build next-generation AI and automation technologies for drug discovery. 

The new name of Iambic Therapeutics reflects its transition to a company with the additional capability of clinical development of candidates identified through its AI-driven discovery platform.  

We’re proud to support this innovative company and welcome Iambic Therapeutics to the Illumina Ventures portfolio.  

Read the full press release: https://lnkd.in/ex3JkGZY

Ascenta Capital 
Abingworth 
NVIDIA
Gradiant Corporation 
Nexus Venture Partners
Catalio Capital Management 
Coatue 
Freeflow Ventures
OrbiMed 
Sequoia Capital

Ron Mazumder 
Charles Lin
Bill Rastetter

HomeLab™ at UC San Diego

#PartnerNews #MachineLearning #AI #ArtificalIntelligence #DrugDiscovery #Healthcare #SanDiego

Hearty congrats to Thomas Miller, Fred Manby, and team Iambic Therapeutics (formerly known as Entos), on securing their Series B round. We are thrilled to have partnered with them from 2020, when we led their seed round, and are delighted to have participated in this round alongside a group of stellar investors. 

We eagerly look forward to Iambic’s continued growth and success as they disrupt the therapeutics landscape with their unique generative AI-driven drug-discovery platform.

Jishnu B. I Nexus Venture Partners I #NexusVP

https://lnkd.in/ex3JkGZY

Iambic Therapeutics (previously #Entos) has successfully closed an oversubscribed $100 million Series B financing round, co-led by Ascenta Capital and Abingworth, with participation from new and existing investors including NVIDIA, #IlluminaVentures, and Sequoia Capital. 

These funds aim to bolster the development of their pioneering AI-driven drug discovery platform and advance several AI-identified therapeutic candidates. With a combined expertise in physics and AI, Iambic strives to revolutionize drug discovery. https://lnkd.in/eymxF8TF

Entos is now Iambic Therapeutics! We are excited to announce that Iambic has closed a $100 Million Series B to continue work on advancing AI-discovered therapeutics into clinical development as we enter a collaboration with NVIDIA.

This funding, co-led by Ascenta Capital and Abingworth, will support new AI platform innovations, advancement of multiple candidates into clinical development, and expansion of internal pipeline  across target classes and therapeutic areas.

Read the full press release at: https://lnkd.in/ex3JkGZY

#DrugDiscovery #ArtificialIntelligence #MachineLearning

Entos co-founder and CEO Thomas Miller joined the AI in Drug Discovery panel at #IDSD23, discussing clinical drug candidates created using the Entos AI-driven drug-discovery platform. A big thanks to Aiden Aceves, Ph.D. at Insight Partners for moderating and Connect for coordinating!

#DrugDiscovery #MachineLearning #AI

We are thrilled to see Entos included in Insider's list of most-promising healthcare start-ups of 2023 for accelerating the delivery of new drugs to clinic with our AI-driven high-throughput drug-discovery platform.

https://lnkd.in/e7MbKMb3

#artificialintelligence #healthcare #machinelearning #drugdiscovery

Join Entos CEO Thomas Miller at the The Camille and Henry Dreyfus Foundation/American Chemical Society Symposium on Machine Learning to learn about advances in AI-driven drug discovery!

Date: Tuesday, August 15, 3pm PT

https://lnkd.in/eZ4_C3Pg

#ACSFall2023 #machinelearning #drugdiscovery #artificialintelligence

AI:IAMBIC

Iambic Therapeutics

Analysis Not Available